MiNK Therapeutics Q2 Earnings Call Highlights
Yahoo Finance · Aug 13, 2026 · Mink Therapeutics Inc (INKT)
MiNK Therapeutics (NASDAQ:INKT) said it initiated dosing in a randomized Phase II trial of its allogeneic invariant natural killer T-cell therapy, agenT-797, for patients with acute lung injury and acute respiratory distress syndrome, or ARDS, during the second quarter of 2026. The company also lau
Not investment advice. Headline and summary only, not a full reprint.